scholarly journals Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy, Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Kumarpillai Gopukumar ◽  
Shefali Thanawala ◽  
Venkateswarlu Somepalli ◽  
T. S. Sathyanaryana Rao ◽  
Vijaya Bhaskar Thamatam ◽  
...  
Keyword(s):  
Placebo Group ◽  
Clinical Study ◽  
Sleep Quality ◽  
Cognitive Functions ◽  
Serum Cortisol ◽  
Well Being ◽  
Root Extract ◽  
Double Blind ◽  
Psychological Well Being ◽  
Stress Levels

Background. The global prevalence of stress is increasing. Stress adversely affects cognitive ability, sleep quality, and overall psychological well-being. Ashwagandha (Withania somnifera (L.) Dunal), an essential medicine in Ayurveda, is reportedly beneficial in reducing stress and improving memory. This double-blind, randomized, placebo-controlled clinical study evaluated the effect of Ashwagandha root extract sustained-release capsule 300 mg (Prolanza™; hereafter Ashwagandha SR) on cognitive functions, stress levels, sleep quality, overall well-being, and safety in stressed subjects. Methods. Subjects (130 healthy cognitively sound adults [20–55 years, body mass index:18–29 kg/m2]) having a Perceived Stress Scale (PSS) score of 14–24 were randomized to receive either Ashwagandha SR or placebo. Subjects took one capsule of Ashwagandha SR or placebo daily for 90 consecutive days. This study was registered on Clinical Trials Registry-India (CTRI) on 13/11/2019 [number: CTRI/2019/11/021990]. The primary endpoint was the change in cognitive function as measured by CANTAB from baseline to the end of the study period (90 ± 7 days). The secondary outcomes included the change in PSS-10 score, serum cortisol level (9–11 am), the OHQ score, the PSQI, and serum BDNF levels. Results. Only 125 completed the study and were evaluated. The Cambridge Neuropsychological Test Automated Battery (CANTAB) reported significantly improved recall memory, and the total error rate in recalling patterns significantly decreased at visit 4 in the Ashwagandha SR group vs. the placebo group (first attempt memory score:12.9 ± 6.7 vs. 10.1 ± 6.3; total errors:17.5 ± 23.3 vs. 27.7 ± 23.6). At visit 4, lower PSS-10 score (13.0 ± 5.0 vs. 18.7 ± 4.6; p < .0001 ), serum cortisol levels p = 0.0443 , and Pittsburgh Sleep Quality Index (PSQI) score p < .0001 but higher Oxford Happiness Questionnaire (OHQ) scores p < .0001 were seen in Ashwagandha SR vs. the placebo group, suggesting significantly lower stress levels and significantly better psychological well-being and sleep quality in the former. No adverse events were reported. Conclusions. This is the first clinical study assessing Ashwagandha SR for its safety and efficacy. Treatment with one Ashwagandha SR capsule once daily for 90 days improved memory and focus, psychological well-being, and sleep quality, reduced stress levels, and was safe and well-tolerated.

scholarly journals IDDF2021-ABS-0165 Psychological well-being and sleep quality among healthy stool donors in singapore: a cross-sectional study

2021 ◽  
Author(s):  
Tzi Shin Toh ◽  
Jonathan Wei Jie Lee ◽  
Kai Yee Toh ◽  
Jia Pei Ho ◽  
Jeremy Fung Yen Lim ◽  
...  
Keyword(s):  
Sleep Quality ◽  
Well Being ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Psychological Well Being

scholarly journals A Prospective Randomized Double-Blind Study Evaluating UP165 and S-Adenosyl-l-Methionine on Depression, Anxiety and Psychological Well-Being

Foods ◽  
2015 ◽  
Vol 4 (4) ◽  
pp. 130-139
Author(s):  
Douglas Kalman ◽  
Samantha Feldman ◽  
Rafeal Vazquez ◽  
Diane Krieger
Keyword(s):  
Well Being ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Psychological Well Being

scholarly journals Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study

2021 ◽  
Vol 18 (5) ◽  
pp. 2561
Author(s):  
Yonghwan Kim ◽  
Hee-Taik Kang ◽  
Duk-Chul Lee
Keyword(s):  
Insulin Resistance ◽  
Mitochondrial Dna ◽  
Placebo Group ◽  
Arterial Stiffness ◽  
Sleep Quality ◽  
Copy Number ◽  
Quality Index ◽  
Controlled Study ◽  
Double Blind ◽  
Randomized Controlled

Melatonin is a hormone produced in the pineal gland that controls sleep and circadian rhythm. Some studies have reported antioxidant and anti-inflammatory effects of melatonin that could benefit cardiometabolic function; however, there is a lack of evidence to support these assertions. The aim of this study was to investigate whether melatonin has beneficial effects on arterial stiffness and mitochondrial deoxyribonucleic acid (DNA) in humans. Methods: This study was designed as a double-blind randomized controlled study. Thirty-eight healthy women aged 55 years and older were enrolled. All had insomnia (Pittsburgh Sleep Quality Index (PSQI) ≥ 5), not treated with any medications, for at least three months before enrollment. Subjects were divided into a melatonin and a placebo group according to melatonin supplementation. The melatonin group took 2 mg melatonin every night for six weeks. The cardio–ankle vascular index (CAVI) was used as an indicator of arterial stiffness. After six weeks, CAVI, mitochondrial DNA (mtDNA) copy number in white blood cells (WBCs), and other metabolic indices, such as homeostasis model assessment of insulin resistance (HOMA-IR), were checked. Results: Sleep quality index using PSQI was improved in the melatonin group from a score of 11 to 8 (p = 0.01), but did not change significantly in the control group. However, there was no significant intergroup difference in PSQI. Systolic blood pressure (SBP) decreased in the melatonin group from 135 to 128 mmHg (p = 0.015), while remaining stable in the placebo group. Right CAVI, mitochondrial DNA copy number, and HOMA-IR were not altered in either group. There were no intergroup differences in CAVI, mtDNA, HOMA-IR, or SBP between baseline and week six. Conclusions: We found no evidence that melatonin supplementation improved cardiometabolic parameters like arterial stiffness, mtDNA, or insulin resistance compared to the placebo between baseline and week six. Sleep quality was improved in the melatonin group. Further research, including longer-term studies with higher doses of melatonin, is warranted.

scholarly journals Hostile Organizational Climate as an Antecedent to Paranoid Cognition and Sleep: Moderating Role of Emotional Suppression

2021 ◽  
Author(s):  
Fatima Bashir ◽  
Saima Naseer
Keyword(s):  
Sleep Quality ◽  
Organizational Climate ◽  
Well Being ◽  
Work Behavior ◽  
Counterproductive Work Behaviors ◽  
Work Behaviors ◽  
Emotional Suppression ◽  
Psychological Well Being ◽  
Moderating Role

Introduction.- Hostile organization climates can pave way for hostile, aggressive behavior and attitude which later become norm of the workplace. The hostile climate in an organization can ensure a damaging impact on employee behavior and mental health. Objectives.- Using Cognitive Activation Theory of Stress (CATS) this study aims to investigate the activation of paranoid cognitions due to stress stimuli coming from explore hostile climate and its impact on the sleep quality of employees which further lead to negative employee outcomes like counterproductive work behaviors, and psychological well-being with the moderating role of emotional suppression. Method and Results.-A time-lagged data segregated at three-time intervals are collected from employees and peers (n=497) working in the Telecom sector of Pakistan. Our study utilized PROCESS in SPSS technique to prove serial mediation of paranoid cognition and sleep quality between hostile climate, counterproductive work behavior, and psychological well-being and moderation analysis. Conclusion.- This study discovers new avenues in the existing literature of CATS and hostile climate by examining paranoid cognition and sleep quality as the underlying mechanisms through which hostile organizational climate can defoliate psychological well-being and can cause harm to an organization through counterproductive work behaviors.

scholarly journals Early pain management after periodontal treatment in dogs – comparison of single and combined analgesic protocols

2015 ◽  
Vol 84 (3) ◽  
pp. 305-311
Author(s):  
Petr Raušer ◽  
Petr Janalík ◽  
Martina Klimešová ◽  
Magdaléna Marková ◽  
Ladislav Stehlík ◽  
...  
Keyword(s):  
Clinical Study ◽  
Visual Analogue Scale ◽  
Plasma Glucose ◽  
Analogue Scale ◽  
Serum Cortisol ◽  
Periodontal Treatment ◽  
Friedman Test ◽  
Nerve Blocks ◽  
Double Blind ◽  
Group B

The aim of this study was to assess the analgesic effectiveness of three analgesic protocols in dogs undergoing a periodontal treatment. The study was performed as a prospective, randomized, “double blind” clinical study. A total of 45 client-owned dogs scheduled for periodontal treatment were included. Dogs of Group C received carprofen (4 mg·kg-1), dogs of Group B received bupivacaine (1 mg·kg-1) and dogs of Group CB received a combination of carprofen (4 mg·kg-1) and bupivacaine (1 mg·kg-1). Carprofen was administered subcutaneously 30 min before anaesthesia, bupivacaine was administered by nerve blocks in anaesthetized dogs. Painful periodontal treatment was performed in all patients, lasting up to one hour. Modified University of Melbourne Pain Score (UMPS), Visual Analogue Scale for pain assessment (VAS), plasma glucose and serum cortisol levels were assessed 30 min before administration of analgesics (C-0, B-0, CB‑0) and 2 h after recovery from anaesthesia (C-2, B-2, CB-2). For statistical analysis Friedman test, Mann-Whitney U-test, ANOVA and Fischer exact tests were used (P < 0.05). In CB‑2 compared to CB‑0 significantly decreased modified UMPS values. In CB‑2 UMPS values were significantly lower compared to C‑2 or B‑2. In C‑2 VAS values were significantly increased compared to C‑0, and in B‑2 VAS values were significantly increased compared to B‑0. Visual Analogue Scale values were significantly lower in CB‑2 compared to C‑2 or B‑2. Significantly increased plasma glucose concentrations were found in C‑2 compared to C‑0 and in B‑2 compared to B‑0. No other significant differences were detected. Administration of carprofen, bupivacaine or their combination is sufficient for early postoperative analgesia following periodontal treatment. Carprofen-bupivacaine combination is superior to carprofen or bupivacaine administered separately.

Sign in / Sign up

Export Citation Format

Share Document